Overview

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Status:
Completed

Trial end date:
2016-01-11

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the safety and tolerability of tirabrutinib (formerly ONO/GS-4059) given as monotherapy to participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Collaborator:

Ono Pharmaceutical Co. Ltd